Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy.
Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy.
复制标题
DOI：
10.1111/ene.12717
复制
发表时间：
2015-07
影响因子：
5.1
通讯作者：
Oaklander AL
中科院分区：
文献类型：
--
作者：
Treister R;O'Neil K;Downs HM;Oaklander AL
最近开发的综合自主神经症状评分-31(COMPASS-31)是一种评估自主神经功能障碍症状的问卷。它是从完善的自主神经症状描述问卷中提炼出来的。Compass-31尚未经过外部验证。为此，我们评估了它的心理测量学特性及其在有或没有客观诊断为小纤维多发性神经病(SFPN)的患者中的收敛有效性。COMPASS-31的内部效度和可靠性在有或没有SFPN的参与者中进行了评估，这些参与者涵盖了全部自主神经症状的严重程度。通过比较COMPASS-31和测量心脏迷走神经、肾上腺素能和运动功能的金标准自主神经功能测试(AFT)的结果来评估收敛的有效性。此外，还评估了COMPASS-31与简明麦吉尔疼痛问卷、简明健康调查和0-10数字疼痛评分之间的关系。COMPASS-31和所有其他问卷的结果在有或没有SFPN证据的患者之间进行了比较，客观地通过小腿远端PGP9.5免疫标记的皮肤活检证实了这一点。在66名被试(28名SFPN+，38名SFPN-)中，COMPASS-31总分具有良好的内部效度(Cronbach‘sα=0.919)、重测信度(rS=0.886；p<；0.001)和良好的收敛效度(rS=0.474；p<；0.001)。COMPASS-31得分在有或没有三叉神经痛的受试者之间有差异(Z=−3.296，p<；0.001)，并显示出相当的诊断准确性。受试者工作特征曲线下面积为0.749(P=0.0195%可信区间0.627~0.871)。COMPASS-31在接受SFPN评估的患者群体中具有良好的心理测量学特性，因此它可能是更昂贵的SFPN客观测试的初始筛查工具。
The recently developed composite autonomic symptom score-31 (COMPASS-31) is a questionnaire for assessing symptoms of dysautonomia. It was distilled from the well established autonomic symptom profile questionnaire. COMPASS-31 has not yet been externally validated. To do so, we assessed its psychometric properties and its convergent validity in patients with or without objective diagnosis of small fiber polyneuropathy (SFPN). The internal validity and reliability of COMPASS-31 were assessed in participants with or without SFPN spanning the full autonomic symptoms severity. Convergent validity was assessed by comparing results of the COMPASS-31 and the gold standard autonomic function testing (AFT) which measures cardiovagal, adrenergic, and sudomotor functions. Additionally, relationships between COMPASS-31 and the Short Form McGill pain questionnaire, Short Form Health Survey and a 0-10 numeric pain scale were assessed. COMPASS-31 and all other questionnaires results were compared between patients with or without evidence of SFPN, objectively confirmed by distal-leg PGP9.5-immunolabeled skin biopsy. Among 66 participants (28 SFPN+, 38 SFPN-), COMPASS-31 total scores had excellent internal validity (Cronbach's α =0.919), test-retest reliability (rs=0.886; p<0.001), and good convergent validity (rs=0.474; p<0.001). COMPASS-31 scores differed between subjects with or without SFPN (Z=−3.296, p<0.001), and demonstrated fair diagnostic accuracy. Area under the receiver operating characteristic curve was 0.749 (P =0.01, 95% confidence interval 0.627-0.871). COMPASS-31 has good psychometric properties in the population of patients being evaluated for SFPN and thus it might be useful as an initial screening tool for the more expensive SFPN objective tests.
登录
查看更多内容
影响因子：
5.1
作者：
Lauria, G.;Hsieh, S. T.;Valls-Sole, J.
通讯作者：
Valls-Sole, J.
影响因子：
8.9
作者：
LOW, PA
通讯作者：
LOW, PA
影响因子：
8.9
作者：
Sletten, David M.;Suarez, Guillermo A.;Singer, Wolfgang
通讯作者：
Singer, Wolfgang
影响因子：
9.9
作者：
Suarez, GA;Opfer-Gehrking, TL;Low, PA
通讯作者：
Low, PA
影响因子：
7.4
作者：
Dworkin, Robert H.;Turk, Dennis C.;Melzack, Ronald
通讯作者：
Melzack, Ronald